TEVA · XBRL financial data

Teva Pharmaceutical Industries financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TEVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	16,659	15,878	14,925	15,846	16,544	17,258
Cost of goods and services sold	8,933	8,284	7,952	8,200	8,481	8,320
Gross profit	7,726	7,594	6,973	7,645	8,064	8,938
Research and development	—	—	98	—	—	—
General and administrative	1,173	1,099	1,180	1,162	1,161	1,287
Other operating income (expense)	40	98	107	49	14	(18)
Operating income (loss)	(3,572)	1,716	(2,099)	433	(303)	2,157
Interest expense	963	891	930	1,029	1,002	916
Income tax expense (benefit)	(168)	211	(638)	(7)	676	(180)
Net income (loss)	(3,990)	417	(2,353)	(559)	(1,639)	1,410
Earnings per share, basic USD per share	(3.64)	0.38	(2.12)	(0.50)	(1.45)	1.23
Earnings per share, diluted USD per share	(3.64)	0.38	(2.12)	(0.50)	(1.45)	1.21
Weighted average shares, basic millions of shares	1,095	1,102	1,110	1,119	1,131	1,145
Weighted average shares, diluted millions of shares	1,095	1,107	1,110	1,119	1,131	1,163

Fiscal years (TEVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2,177	2,165	2,801	3,226	3,300	3,556
Accounts receivable	4,581	4,529	3,696	3,408	3,059	3,709
Inventory	4,403	3,818	3,833	4,021	3,007	3,179
Total current assets	13,005	12,573	12,051	12,485	12,552	13,946
Property and equipment, net	6,296	5,982	5,739	5,750	4,581	4,080
Right-of-use asset	559	495	419	397	367	345
Goodwill	20,624	20,040	17,633	17,177	15,147	16,000
Total assets	50,640	47,666	44,006	43,479	39,326	40,748
Accounts payable	—	—	—	108	158	225
Accrued liabilities	—	23	—	—	—	—
Current portion of long-term debt	2,674	1,403	2,086	1,649	1,758	1,798
Total current liabilities	13,164	11,027	11,469	12,247	12,796	13,456
Lease liability, non-current	479	416	349	320	296	288
Total liabilities	39,579	36,422	35,315	35,353	33,606	32,834
Accumulated deficit	(10,946)	(10,529)	(12,882)	(13,534)	(15,173)	(13,762)
Total stockholders' equity	10,026	10,278	7,897	7,506	5,373	7,910
Total liabilities and equity	50,640	47,666	44,006	43,479	39,326	40,748
Common shares outstanding (cover page) millions of shares	1,097	1,103	1,111	1,121	1,134	1,150

Fiscal years (TEVA's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(3,990)	417	(2,353)	(559)	(1,639)	1,410
Stock-based compensation	129	119	124	121	123	157
Net cash from operating activities	1,216	798	1,590	1,368	1,247	1,649
Purchases of property and equipment	578	562	548	—	—	—
Net cash from investing activities	863	1,523	656	968	792	737
Repayments of long-term debt	1,871	6,649	1,369	4,152	1,641	4,112
Net cash from financing activities	(1,885)	(2,172)	(1,487)	(1,913)	(1,791)	(2,151)
Net change in cash	202	21	636	393	74	256

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	—	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	—	Q3 FY26 10-QSep 30, 2026
INSMED	397	524	(36)*	219.4M	—	Q3 FY26 10-QSep 30, 2026
BeOne Medicines	5,098	1,705	463*	1.5B	—	Q2 FY26 10-QJun 30, 2026
United Therapeutics	1,189	833	not reported	42.6M	—	Q3 FY26 10-QSep 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.